International Journal of Laboratory Hematology

LETTER TO THE EDITOR

T-Cell Prolymphocytic Leukemia With PDGFRB Rearrangement in the Setting of Neurofibromatosis Type 1

Yue Zhao

Department of Pathology, First Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, China

Search for more papers by this author

Philip Petersen,

Philip Petersen

Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, California, USA

Search for more papers by this author

Imran Siddiqi,

Imran Siddiqi

Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, California, USA

Search for more papers by this author

Endi Wang,

Corresponding Author

Endi Wang

[email protected]

orcid.org/0000-0001-6132-6336

Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, California, USA

Correspondence:

Endi Wang ([email protected])

Search for more papers by this author

Yue Zhao,

Yue Zhao

Department of Pathology, First Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, China

Search for more papers by this author

Philip Petersen,

Philip Petersen

Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, California, USA

Search for more papers by this author

Imran Siddiqi,

Imran Siddiqi

Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, California, USA

Search for more papers by this author

Endi Wang,

Corresponding Author

Endi Wang

[email protected]

orcid.org/0000-0001-6132-6336

Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, California, USA

Correspondence:

Endi Wang ([email protected])

Search for more papers by this author

First published: 16 January 2025

https://doi.org/10.1111/ijlh.14427

Funding: The authors received no specific funding for this work.

Share a link

Email
Wechat
Bluesky

No abstract is available for this article.

Open Research

Data Availability Statement

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

References

1 D. A. Arber, A. Orazi, R. P. Hasserjian, et al., “International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating Morphologic, Clinical, and Genomic Data,” Blood 140, no. 11 (September 2022): 1200–1228, https://doi.org/10.1182/blood.2022015850.
10.1182/blood.2022015850
CAS PubMed Web of Science® Google Scholar
2 J. D. Khoury, E. Solary, O. Abla, et al., “The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms,” Leukemia 36, no. 7 (July 2022): 1703–1719, https://doi.org/10.1038/s41375-022-01613-1.
10.1038/s41375-022-01613-1
PubMed Web of Science® Google Scholar
3 M. Yamamoto, K. Ikuta, Y. Toki, et al., “Angioimmunoblastic T-Cell Lymphoma and Hypereosinophilic Syndrome With FIP1L1/PDGFRA Fusion Gene Effectively Treated With Imatinib: A Case Report,” Medicine (Baltimore) 96, no. 36 (September 2017): e8001, https://doi.org/10.1097/MD.0000000000008001.
10.1097/MD.0000000000008001
PubMed Web of Science® Google Scholar
4 A. C. Hirbe and D. H. Gutmann, “Neurofibromatosis Type 1: A Multidisciplinary Approach to Care,” Lancet Neurology 13, no. 8 (August 2014): 834–843, https://doi.org/10.1016/S1474-4422(14)70063-8.
10.1016/S1474-4422(14)70063-8
PubMed Web of Science® Google Scholar
5 F. Fareez, B. H. Wang, I. Brain, and J. Q. Lu, “Lymphomas in Patients With Neurofibromatosis Type 1 (NF1): Another Malignancy in the NF1 Syndrome?,” Pathology 55, no. 3 (April 2023): 302–314, https://doi.org/10.1016/j.pathol.2023.01.002.
10.1016/j.pathol.2023.01.002
CAS PubMed Google Scholar
6 P. R. Cohen, “Chronic Lymphocytic Leukemia in Neurofibromatosis Type 1 Patients: Case Report and Literature Review of a Rare Occurrence,” Cureus 13, no. 4 (April 2021): e14258, https://doi.org/10.7759/cureus.14258.
10.7759/cureus.14258
PubMed Google Scholar
7 M. Maccaferri, V. Pierini, D. Di Giacomo, et al., “The Importance of Cytogenetic and Molecular Analyses in Eosinophilia-Associated Myeloproliferative Neoplasms: An Unusual Case With Normal Karyotype and TNIP1- PDGFRB Rearrangement and Overview of PDGFRB Partner Genes,” Leukemia & Lymphoma 58, no. 2 (February 2017): 489–493, https://doi.org/10.1080/10428194.2016.1197396.
10.1080/10428194.2016.1197396
CAS PubMed Web of Science® Google Scholar
8 M. Yamazaki, C. Nakaseko, M. Takeuchi, et al., “Myeloid/Lymphoid Neoplasm With PDGFRB Rearrangement With t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene,” Internal Medicine 58, no. 23 (December 2019): 3449–3453, https://doi.org/10.2169/internalmedicine.3220-19.
10.2169/internalmedicine.3220-19
PubMed Web of Science® Google Scholar
9 S. Qu, Y. Yan, C. Li, et al., “Case of Cryptic TNIP1::PDGFRB Rearrangement Presenting With Myelodysplastic Syndrome Achieved Hematologic and Cytogenetic Remission With Low-Dose Imatinib Plus Decitabine Therapy,” Leukemia Research Reports 19 (2023): 100367, https://doi.org/10.1016/j.lrr.2023.100367.
10.1016/j.lrr.2023.100367
CAS PubMed Web of Science® Google Scholar
10 G. J. Gleich, K. M. Leiferman, A. Pardanani, A. Tefferi, and J. H. Butterfield, “Treatment of Hypereosinophilic Syndrome With Imatinib Mesilate,” Lancet 359, no. 9317 (May 2002): 1577–1578, https://doi.org/10.1016/S0140-6736(02)08505-7.
10.1016/S0140-6736(02)08505-7
CAS PubMed Web of Science® Google Scholar

Volume47, Issue3

June 2025

Pages 541-543

T-Cell Prolymphocytic Leukemia With PDGFRB Rearrangement in the Setting of Neurofibromatosis Type 1

Open Research

Data Availability Statement

References

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

T-Cell Prolymphocytic Leukemia With PDGFRB Rearrangement in the Setting of Neurofibromatosis Type 1

Open Research

Data Availability Statement

References

References

Related

Information